Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Claims Favorable Court Ruling in Case Versus Illumina

This article has been updated with comments from Illumina.

NEW YORK (GenomeWeb News) – Complete Genomics today said that the US District Court for the Northern District of California has granted partial summary judgment in favor of the firm regarding certain claims in an ongoing patent infringement suit with Illumina.

The court decision stems from a lawsuit brought by Illumina against Complete Genomics in August 2010 alleging that Complete Genomics infringes Illumina's US Patent No. 6,306,597. That suit also includes claims that Complete Genomics was infringing US Patent Nos. 7,232,656 and 7,598,035. All of the patents in the suit cover DNA sequencing by parallel oligonucleotide extensions, the use of arrayed biomolecules in sequencing, and methods and compositions for ordering restriction fragments.

Earlier this year Judge Elizabeth Laporte of the US District Court for the Northern District of California issued a claims construction order only on the '597 patent, which Illumina had said was "favorable" to its case for the key terms in the litigation.

In the decision earlier this week, Laporte ruled that Claim 1 and dependent Claims 9, 10, 14, 15, 16, 17, 18, and 19 of the '597 patent are all invalid due to prior art. According to Complete Genomics, the remaining allegation in the lawsuit is that Complete Genomics infringes Claims 2, 4, and 5 of the '597 patent.

"Given the Court's prior claim construction order, Complete strongly believes that it does not infringe these Claims and intends to continue to vigorously defend itself," Complete Genomics said in a statement.

"We strongly disagree that any of the claims of our patent are invalid, and we intend to appeal the Court's ruling," Illumina President and CEO Jay Flatley said in a statement after the close of the market Thursday. "We believe that this patent
covers important and novel inventions that Complete Genomics has misappropriated."

In June Illumina filed a second suit against Complete Genomics alleging infringement of its US Patent No. 8,192,930, entitled "Method for sequencing a polynucleotide template."

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.